Stem Cell Therapies Are a Hot Biopharma Sector and Investors May Want to Look at These Players

Stem Cell Therapies Are a Hot Biopharma Sector and Investors May Want to Look at These Players

Stem cell regenerative therapies, for a variety of indications, are at the leading edge of biopharma technology. The science in stem cell research has advanced significantly over the past decade, and now billions of stem cells can be replicate from a single human donor cell. But the stigma of stem cells being taken from human embryos still hangs over the sector by the uninformed.


The companies involved in developing stem cell therapied present an opportunity for investors as many of them are still undervalued yet have products in clinical trials that if/when approved by the FDA could cause their values to explode and I want to look at a couple.


iSpecimen Inc. (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists with healthcare providers that have access to patients and specimens needed for medical discovery.


When labs working on stem cell therapies need that human donor stem cell to replicate, how do they get it? They could go online and order it from ISPC. They have the stem cell products biopharma researchers need that contain primary cells utilized in autoimmune and infectious disease research, drug discovery and preclinical development, such as:


Hematopoietic stem cells (HSCs or CD34+): oligopotent stem cells that give rise to each mature blood cell type.


Mesenchymal stem cells (MSCs): in unprocessed whole bone marrow aspirate (bone marrow stromal stem cells), multipotent stem cells capable of differentiating into osteoblasts, myocytes, adipocytes, chondrocytes; MSCs also possess immunomodulatory function


Immune cells: Pan T (CD3+), Helper T (CD4+), Cytotoxic T (CD8+), NK (CD 56+), B cells (CD 19+), Monocytes (CD14+), antigen presenting cells (dendritic), neutrophils, macrophages, and related cell types.


ISPC has a tiny share structure, $10M (ttm) revenues, and a market cap at only $18M. Investors may want to consider this unique player in the stem cell biopharma sector.



Athersys, Inc. (NASDAQ: ATHX) has seven clinical trials in progress to treat ischemic stroke, acute respiratory distress syndrome, and trauma based upon their unique MultiStem Cell Therapy (invimestrocel) derived from the bone marrow of healthy, consenting adult donors.


ATHX is currently in a Phase 3 clinical trial being conducted primarily in North America and Europe to treat ischemic stroke. The trial falls under an FDA Special Protocol Assessment, or SPA. In addition, this program received the Fast Track designation, as well as the Regenerative Medicine Advanced Therapy, or RMAT, designation from the FDA. The company is also involved in a preclinical study for the Department of Defense to determine the regenerative efficacy of their product to treat radiation exposure.


The company completed a 25 for 1 reverse stock split in late August reducing its outstanding share count to 12M and is currently negotiating a $12M capital raise with a private institutional investor that specializes in healthcare companies.


Update: New Report 9-26-22 Grom Social (NASDAQ: GROM) May be on the verge of a deal with streaming service like $DIS, $NFLX, $HULU or $AMZN – FULL REPORT HERE 


The Traders News Group


Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails.
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice.
All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have not been compensated for the mention of athx, ispc, dis, nflx, amzn or hulu. The owners and operators of this website have been compensated twelve thousand five hundred dollars cash via bank wire by grom social enterprises for this weeks updated distributed opinions on grom. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.
TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.